Literature DB >> 14572683

Chronotherapy for cancer.

M Eriguchi1, F Levi, T Hisa, H Yanagie, Y Nonaka, Y Takeda.   

Abstract

Cancer chronotherapy is attracting attention as a novel and logical therapy in which anti-cancer drugs are administered with optimal timing according to circadian rhythms of anti-cancer action and those of adverse effects on normal cells. Advances in chronobiology have identified the suprachiasmatic nucleus (SCN) as the center of biological rhythms and the area in which clock genes such as PER1, PER2, PER3, CLOCK, BMAL1, TIM, CRY1, CRY2, tau act to generate and coordinate biological rhythms. These findings have led to the development of chronotherapy. Clinically, patients with advanced gastrointestinal cancer have been treated by chronomodulated chemotherapy with good response. For colorectal cancer patients with unresectable liver metastases, chronotherapy with l-OHP + 5-FU + FA (folinic acid) has been reported to allow complete surgical resection of liver metastases, resulting in 39-50% 5-year survival. Many believe that chronotherapy will become accepted as a refined and advantageous therapeutic option for not only cancer but also for other diseases, due to its universally applicable principles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14572683     DOI: 10.1016/j.biopha.2003.08.012

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  15 in total

1.  Metabolism control by the circadian clock and vice versa.

Authors:  Kristin Eckel-Mahan; Paolo Sassone-Corsi
Journal:  Nat Struct Mol Biol       Date:  2009-05       Impact factor: 15.369

Review 2.  Enabling individualized therapy through nanotechnology.

Authors:  Jason H Sakamoto; Anne L van de Ven; Biana Godin; Elvin Blanco; Rita E Serda; Alessandro Grattoni; Arturas Ziemys; Ali Bouamrani; Tony Hu; Shivakumar I Ranganathan; Enrica De Rosa; Jonathan O Martinez; Christine A Smid; Rachel M Buchanan; Sei-Young Lee; Srimeenakshi Srinivasan; Matthew Landry; Anne Meyn; Ennio Tasciotti; Xuewu Liu; Paolo Decuzzi; Mauro Ferrari
Journal:  Pharmacol Res       Date:  2010-01-05       Impact factor: 7.658

Review 3.  Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer.

Authors:  Brittney Jung-Hynes; Russel J Reiter; Nihal Ahmad
Journal:  J Pineal Res       Date:  2010-01       Impact factor: 13.007

4.  Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer.

Authors:  Joan Climent; Jesus Perez-Losada; David A Quigley; Il-Jin Kim; Reyno Delrosario; Kuang-Yu Jen; Ana Bosch; Ana Lluch; Jian-Hua Mao; Allan Balmain
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

5.  Radiation chronotherapy-clinical impact of treatment time-of-day: a systematic review.

Authors:  Dorela D Shuboni-Mulligan; Ghislain Breton; DeeDee Smart; Mark Gilbert; Terri S Armstrong
Journal:  J Neurooncol       Date:  2019-11-15       Impact factor: 4.130

6.  Circadian variation in expression of G1 phase cyclins D1 and E and cyclin-dependent kinase inhibitors p16 and p21 in human bowel mucosa.

Authors:  John Griniatsos; Othon P Michail; Stamatios Theocharis; Antonios Arvelakis; Ioannis Papaconstantinou; Evangelos Felekouras; Emmanouel Pikoulis; Ioannis Karavokyros; Chris Bakoyiannis; George Marinos; John Bramis; Panayiotis O Michail
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

Review 7.  Understanding the significance of biological clock and its impact on cancer incidence.

Authors:  Shalie Malik; James Stokes Iii; Upender Manne; Rajesh Singh; Manoj K Mishra
Journal:  Cancer Lett       Date:  2021-12-11       Impact factor: 8.679

8.  A common polymorphism near PER1 and the timing of human behavioral rhythms.

Authors:  Andrew S P Lim; Anne-Marie Chang; Joshua M Shulman; Towfique Raj; Lori B Chibnik; Sean W Cain; Katherine Rothamel; Christophe Benoist; Amanda J Myers; Charles A Czeisler; Aron S Buchman; David A Bennett; Jeanne F Duffy; Clifford B Saper; Philip L De Jager
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

9.  Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery.

Authors:  Laura E Strong; Shreyas N Dahotre; Jennifer L West
Journal:  J Control Release       Date:  2014-01-23       Impact factor: 9.776

10.  Circadian genes Per1 and Per2 increase radiosensitivity of glioma in vivo.

Authors:  Niu Zhanfeng; Li Yanhui; Fei Zhou; Hao Shaocai; Li Guangxing; Xia Hechun
Journal:  Oncotarget       Date:  2015-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.